The company's stock took a hit after the investment firm downgraded it to "underweight" from "neutral."
R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.
The investment firm noted the "enormous" market opportunity for Exact Sciences' Cologuard test and predicted it would receive FDA clearance in 2013.
All of the banks issued favorable recommendations on the molecular diagnostics firm's stock.
The bank also placed a price target of $52 on Illumina's stock.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.